Excellent idea. Please use all your influence to make it happen.
someone msg bryan johnson this
i bet he will be willing to do the n=1 exploratory clinical trial phase 2-3 via tiktok for us
A new study out of Helen Blau’s lab at Stanford:
Rescuing Muscle on Ozempic: 15-PGDH Inhibition Restores Regenerative Capacity During GLP-1 Weight Loss
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide, are highly effective pharmacological tools for weight reduction but consistently induce significant skeletal muscle attrition. While resting muscle strength and specific force might remain stable under GLP-1 RA treatment, the physiological deficit manifests acutely during muscle repair and hypertrophy. A recent study reveals that semaglutide drastically blunts the proliferative capacity of resident muscle stem cells (MuSCs) during tissue regeneration following an injury.
To counteract this regenerative failure, researchers utilized a pharmacological inhibitor of 15-hydroxyprostaglandin dehydrogenase (15-PGDH). 15-PGDH functions as a “gerozyme” that degrades prostaglandin E2 (PGE2), a crucial lipid messenger required for stem cell expansion and muscle repair. By co-administering the 15-PGDH inhibitor (PGDHi) alongside semaglutide in diet-induced obese mice, researchers successfully rescued MuSC proliferation and restored regenerating myofiber size.
Critically, the 15-PGDH inhibitor achieved this localized anabolic rescue without compromising the potent fat-loss, systemic metabolic, and appetite-suppressing benefits of the GLP-1 therapy. Furthermore, semaglutide provided a secondary protective effect by preventing pathological calcification and fibrosis during the muscle healing process, a benefit that remained intact during PGDHi co-administration. This introduces a highly synergistic pharmacological strategy: utilizing a GLP-1 RA for robust metabolic correction while deploying a PGDHi to maintain stem cell resilience, structural tissue integrity, and functional strength. [Confidence: High]
Source:
- Open Access Paper: 15-PGDH Inhibition Overcomes Muscle Regenerative Deficit Seen With GLP1-Receptor Agonist-Induced Weight Loss
- Institution: Stanford University School of Medicine, Arc Institute, University of California, Davis.
- Country: United States.
- Journal: bioRxiv.
Impact Evaluation: The impact score of this journal is N/A (Preprint Server),
4 Likes
Saw a study the other day which I cant find which suggests glp 1 agonists were protective of cartilage independent of the weight loss effect - in fact it was suggesting that cartilage thickened. So put pgdh-15 inhibitors together with glp 1 agonists then have you got a heavenly match for cartilage?
This study isnt the one im looking for but its close.
2 Likes
The ethanolic extract in the studies was 50% ethanol. An extraction made with pure ethanol was ineffective. I made 50% ethanol by mixing 190 proof Everclear vodka with water in a 10 to 9 ratio. I put this in a double boiler with jackfruit leaves and let it simmer for several hours, poured off and reserved the liquid, added more 50% ethanol and repeated. Then combined the liquids.
The non water soluble components precipitated out of solution. I could have continued concentrating the extract until I had a dry powder, but decided to stir well and drink a half ounce of the liquid at a time. After a few days I can confirm it has had one hell of a placebo effect. Maybe more than that.
Commercial availability of the dried extract could take less than a year.
4 Likes
I’ll buy it! Heres the a piece on the study i couldnt find… Semaglutide May Reverse Damage Caused by Osteoarthritis, Study Suggests : ScienceAlert